Table 12Key outcomes of nonhormonal pharmacologic treatments for noncyclic CPP

Author, Year, Country
Quality
Intervention, N at Enrollment (N at Followup)Last Outcome Assessment Post Treatment Day 1Key Findings
Abbot et al., 2006,95 Australia

Quality: Fair
G1: Botulinum toxin type A, 80 units, 30 (29)
G2: Placebo (saline), 30 (28)
6 months after injection
  • Botulinum toxin treatment group showed significant improvement in nonmenstrual pelvic pain scores (p=0.009); the placebo group did not
  • Significantly decreased pelvic floor pressures from baseline in both treatment groups (p<0.001, p=0.003)
  • Notable events/serious complications occurred in 4 women in the botulinum toxin group
Sator-Katzenschlager et al., 2005,71 Austria

Quality: Poor
G1: Gabapentin, maximum 3600 mg/day, 20 (17)
G2: Amitriptyline, maximum 150 mg/day, 20 (17)
G3: Gabapentin + amitriptyline, 16 (15)
At the end of 24 months of treatment
  • All patients experienced significant pain relief during treatment and at the end of treatment, compared with baseline scores
  • Between groups, pain reduction was significantly greater in those who received gabapentin alone or gabapentin/amitriptyline combination compared with those who received amitriptyline alone
  • Incidence of dose-limiting side effects was lower in the gabapentin group, compared with the other 2 groups
  • No significant difference between groups in the incidence of severe side effects (those requiring discontinuation of treatment)

Abbreviations: CPP = noncyclic chronic pelvic pain; G = group; mg = milligram; N = number.

From: Results

Cover of Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness
Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 41.
Andrews J, Yunker A, Reynolds WS, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.